LON:NIOX
Niox Group PLC
Position levels
Currenttoday
60.40p
Buy <=wait / entry
56.00p
Trim >=take some off
72.00p
Thesis breakA sustained deceleration in FeNO clinical and research revenue to single-digit g...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 25% | 100 / 100 | 25.0 |
| Base case | 50% | 62 / 100 | 31.0 |
| Bear case | 25% | 10 / 100 | 2.5 |
| Weighted conviction | 59 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- Research revenue growth of 108% to GBP 5.2 million in H1 2025 driven by increased clinical trial activity
- Group revenue growth of 20% to GBP 25.2 million and adjusted EBITDA growth of 30% to GBP 9.2 million with margin expansion to 36.5%
- Full year 2024 revenue growth of 14% to GBP 41.8 million and adjusted EBITDA growth of 21% to GBP 13.8 million